9-me-bc 15mg – 60 capsules

9-Me-BC (9-Methyl-β-Carboline) 15 mg — 60 oral research capsules. 9-Methyl-β-carboline is one of the most pharmacologically distinctive small-molecule neuroprotective compounds in the research literature — and one of very few molecules ever shown to combine genuine dopaminergic neurorestoration with concurrent neurogenesis and anti-inflammatory activity in a single chemotype. Originating from the laboratory of Hans Rommelspacher at the Free University of Berlin, 9-Me-BC has been characterized over more than a decade in dopaminergic neuron culture systems and rodent Parkinson’s disease models, where short-term oral administration restores tyrosine hydroxylase expression, induces proliferation of dopamine progenitor cells, and rescues behavioral deficits.

Research Overview

β-Carbolines are a family of tricyclic indole alkaloids found endogenously in human brain and cerebrospinal fluid as well as in plants (Peganum harmala), tobacco smoke and roasted coffee [1]. 9-Methyl-β-carboline is a synthetic, methylated derivative whose pharmacology departs sharply from the parent norharman: rather than the MAO-A-inhibitory profile of unmethylated β-carbolines, 9-Me-BC exhibits a complex but reproducible profile of dopaminergic neuroprotection, neurogenesis and anti-inflammatory activity in primary mesencephalic neuron cultures and in vivo [1,2]. Mechanistic work has identified upregulation of GDNF, BDNF and tyrosine-hydroxylase expression, suppression of microglial activation, and increased proliferation of dopaminergic progenitors as core features [2]. In MPTP and 6-OHDA rodent models of Parkinson’s disease, oral 9-Me-BC at clinically relevant doses partially restores striatal dopamine, rescues motor performance and induces measurable hippocampal neurogenesis [3]. The compound has emerged as one of the most distinctive research tools available for combined neuroprotective-neurogenic pharmacology — a profile not replicated by any approved neurodegenerative-disease drug.

Primary Research Areas

• Dopaminergic neuroprotection and neurorestoration — consistent restoration of TH expression, dopamine content and motor function in MPTP and 6-OHDA Parkinson’s models [1,2].
• Adult neurogenesis — induces proliferation of dopaminergic progenitor cells and increases hippocampal neurogenesis in vivo [2,3].
• Neurotrophic factor upregulation — documented increases in GDNF, BDNF and other neurotrophic factor expression — a rare combination in a single chemotype [2].
• Anti-neuroinflammatory pharmacology — suppresses microglial activation and pro-inflammatory cytokine release in primary microglia and in vivo [1].
• β-carboline structure-activity research — reference compound for studying how N9-methylation reshapes β-carboline pharmacology away from the MAO-A-inhibitory parent profile [1].

References

1. Polanski W, Reichmann H, Gille G. Stimulation, protection and regeneration of dopaminergic neurons by 9-methyl-β-carboline: a new anti-Parkinson drug? Expert Rev Neurother. 2011;11(12):1763–1771.
2. Hamann J, Wernicke C, Lehmann J, Reichmann H, Rommelspacher H, Gille G. 9-Methyl-β-carboline up-regulates the appearance of differentiated dopaminergic neurones in primary mesencephalic culture. Neurochem Int. 2008;52(4-5):688–700.
3. Polanski W, Enzensperger C, Reichmann H, Gille G. The exceptional properties of 9-methyl-β-carboline: stimulation, protection and regeneration of dopaminergic neurons. J Neurochem. 2010;113(6):1659–1675.